Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

The molecular basis of breast cancer pathological phenotypes.

Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman FM, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen GM, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH.

J Pathol. 2017 Feb;241(3):375-391. doi: 10.1002/path.4847. Epub 2016 Dec 29.

2.

Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.

Sanders H, Qu K, Li H, Ma L, Barlan C, Zhang X, Prentice J, Wolfson D, Crossley B, Sferruzza A, Sninsky J, Ross D, Grupe A, Catanese J, Hantash F, Waldman F.

Mol Diagn Ther. 2016 Jun;20(3):241-53. doi: 10.1007/s40291-016-0197-0.

PMID:
27084556
3.

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.

Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS.

Thyroid. 2016 Feb;26(2):227-34. doi: 10.1089/thy.2015.0401. Epub 2016 Jan 7.

4.

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.

Li Y, Bare LA, Bender RA, Sninsky JJ, Wilson LS, Devlin JJ, Waldman FM.

Mol Diagn Ther. 2015 Jun;19(3):169-77. doi: 10.1007/s40291-015-0140-9.

5.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

6.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC.

Breast Cancer Res. 2013;15(5):R103.

7.

Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.

Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, Nguyen D, Jones D, Waldman F.

J Mol Diagn. 2013 Nov;15(6):790-5. doi: 10.1016/j.jmoldx.2013.07.003. Epub 2013 Aug 28.

PMID:
23994118
8.

Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ.

Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, Schnitt SJ, Waldman FM, Chen YY.

Hum Pathol. 2013 Oct;44(10):1998-2009. doi: 10.1016/j.humpath.2013.04.004. Epub 2013 Jun 25.

PMID:
23809857
9.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4. Epub 2013 May 28.

PMID:
23712790
10.

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3. Epub 2012 Oct 27.

11.

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM.

Oncogenesis. 2012 Jun 25;1:e14. doi: 10.1038/oncsis.2012.14.

12.

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.

PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312. Epub 2011 Oct 13.

13.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA; Cancer and Leukemia Group B Pathology Committee.

J Clin Oncol. 2011 Jun 1;29(16):2282-90. doi: 10.1200/JCO.2010.33.2023. Epub 2011 Apr 25.

14.

Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ.

Hwang ES, Lal A, Chen YY, DeVries S, Swain R, Anderson J, Roy R, Waldman FM.

Hum Pathol. 2011 Oct;42(10):1467-75. doi: 10.1016/j.humpath.2011.01.002. Epub 2011 Apr 14.

PMID:
21496874
15.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14.

16.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

17.

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.

Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A.

Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Epub 2010 Mar 29. Review.

18.

TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.

Szymańska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M, Janout V, Kollarova H, Zaridze D, Matveev V, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Le Calvez-Kelm F, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P.

Cancer Lett. 2010 Jul 1;293(1):92-8. doi: 10.1016/j.canlet.2009.11.024. Epub 2010 Feb 6.

PMID:
20137853
19.

Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.

Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F.

Mod Pathol. 2009 Nov;22(11):1477-88. doi: 10.1038/modpathol.2009.119. Epub 2009 Sep 4.

20.

Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, Fitzgibbons PL, Jacobs TW, MacGrogan G, Peterse H, Vincent-Salomon A, Tokuyasu T, Schnitt SJ, Waldman FM.

Am J Surg Pathol. 2009 Nov;33(11):1683-94. doi: 10.1097/PAS.0b013e3181b18a89.

21.

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES.

BMC Cancer. 2009 Aug 18;9:285. doi: 10.1186/1471-2407-9-285.

22.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ.

J Clin Oncol. 2009 Aug 20;27(24):3929-37. doi: 10.1200/JCO.2008.18.5744. Epub 2009 Jul 20.

23.

Predictive models in external beam radiotherapy for clinically localized prostate cancer.

Roach M 3rd, Waldman F, Pollack A.

Cancer. 2009 Jul 1;115(13 Suppl):3112-20. doi: 10.1002/cncr.24348. Review.

24.

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES.

Clin Cancer Res. 2009 May 1;15(9):3163-71. doi: 10.1158/1078-0432.CCR-08-2319. Epub 2009 Apr 21.

25.

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.

Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F.

BMC Cancer. 2008 Nov 21;8:339. doi: 10.1186/1471-2407-8-339.

26.

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT.

Oncogene. 2009 Jan 15;28(2):306-12. doi: 10.1038/onc.2008.384. Epub 2008 Oct 13.

27.

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.

Clin Cancer Res. 2008 Aug 1;14(15):4726-34. doi: 10.1158/1078-0432.CCR-07-4921.

28.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
29.

Tissue-based research in kidney cancer: current challenges and future directions.

Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB.

Clin Cancer Res. 2008 Jun 15;14(12):3699-705. doi: 10.1158/1078-0432.CCR-07-4733. Review.

30.

Comparative genomic hybridization.

DeVries S, Gray JW, Pinkel D, Waldman FM, Sudar D.

Curr Protoc Hum Genet. 2001 May;Chapter 4:Unit4.6. doi: 10.1002/0471142905.hg0406s06.

PMID:
18428281
31.

A sequence-based survey of the complex structural organization of tumor genomes.

Raphael BJ, Volik S, Yu P, Wu C, Huang G, Linardopoulou EV, Trask BJ, Waldman F, Costello J, Pienta KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Sridharan S, Paris PL, Tao Q, Aerni SJ, Brown RP, Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC.

Genome Biol. 2008;9(3):R59. doi: 10.1186/gb-2008-9-3-r59. Epub 2008 Mar 25.

32.

Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.

Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ.

Cancer. 2007 Jun 25;111(3):185-91.

33.

Identification of a robust gene signature that predicts breast cancer outcome in independent data sets.

Korkola JE, Blaveri E, DeVries S, Moore DH 2nd, Hwang ES, Chen YY, Estep AL, Chew KL, Jensen RH, Waldman FM.

BMC Cancer. 2007 Apr 11;7:61.

34.

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW.

Cancer Cell. 2006 Dec;10(6):529-41.

35.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

36.

Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA, Werb Z.

Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2107-14.

37.

Chromosomal instability in microsatellite-unstable and stable colon cancer.

Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, Fridlyand J, Snijders AM, Albertson DG, Thibodeau SN, Waldman FM.

Clin Cancer Res. 2006 Nov 1;12(21):6379-85.

38.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.

Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED.

Oncol Rep. 2006 Oct;16(4):807-10.

PMID:
16969498
39.

Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer.

Goodson WH, Moore DH, Waldman FM.

J Clin Oncol. 2006 Aug 10;24(23):3809; author reply 3809. No abstract available.

PMID:
16896010
40.

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM.

BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7.

41.

Breast tumor copy number aberration phenotypes and genomic instability.

Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG.

BMC Cancer. 2006 Apr 18;6:96.

42.

Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer.

Deng G, Nguyen A, Tanaka H, Matsuzaki K, Bell I, Mehta KR, Terdiman JP, Waldman FM, Kakar S, Gum J, Crawley S, Sleisenger MH, Kim YS.

Int J Cancer. 2006 Jun 15;118(12):2999-3005.

43.

Bladder cancer stage and outcome by array-based comparative genomic hybridization.

Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22.

44.

Bladder cancer outcome and subtype classification by gene expression.

Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM.

Clin Cancer Res. 2005 Jun 1;11(11):4044-55.

45.

Securin is overexpressed in breast cancer.

Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP.

Mod Pathol. 2005 Jul;18(7):985-90.

46.

Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.

Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM.

Clin Cancer Res. 2005 Mar 1;11(5):1791-7.

47.

Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):413-5. Review. No abstract available.

48.
49.

Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors.

Devries S, Nyante S, Korkola J, Segraves R, Nakao K, Moore D, Bae H, Wilhelm M, Hwang S, Waldman F.

J Mol Diagn. 2005 Feb;7(1):65-71.

50.

CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.

Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J, Waldman FM, Basbaum C.

Int J Cancer. 2005 Mar 20;114(2):182-9.

Supplemental Content

Loading ...
Support Center